PMGC HOLDINGS INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
PMGC HOLDINGS INC. (ELAB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $965.08K.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $116.49K, a 55.14% decline year-over-year.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $692.22K.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $434.81K, a 151.32% increase year-over-year.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $957.76K, a 361.58% increase from fiscal 2024.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $207.50K, a 55.56% decline from fiscal 2023.
- PMGC HOLDINGS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $466.89K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $965.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.08M 10-Q · filed 2026-08-14 | $1.77M derived: sum of 3 quarters · filed 2026-08-14 | $2.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $116.49K 10-Q · filed 2026-05-15 | $808.71K derived: sum of 2 quarters · filed 2026-05-15 | $1.24M derived: sum of 3 quarters · filed 2026-05-15 | $814.59K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $692.22K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.13M derived: sum of 2 quarters · filed 2026-03-30 | $698.10K derived: sum of 3 quarters · filed 2026-08-14 | $957.76K 10-K · filed 2026-03-30 |
| 2025-09-30 | $434.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.88K derived: sum of 2 quarters · filed 2026-08-14 | $265.54K 10-Q · filed 2025-11-14 | $89.92K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$428.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$169.27K 10-Q · filed 2026-08-14 | -$344.89K derived: sum of 3 quarters · filed 2026-08-14 | -$171.88K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $259.66K 10-Q · filed 2026-05-15 | $84.04K derived: sum of 2 quarters · filed 2026-05-15 | $257.05K derived: sum of 3 quarters · filed 2026-05-15 | $607.86K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$175.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$2.61K derived: sum of 2 quarters · filed 2026-03-30 | $348.19K derived: sum of 3 quarters · filed 2026-03-30 | $207.50K 10-K · filed 2026-03-30 |
| 2024-09-30 | $173.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $523.82K derived: sum of 2 quarters · filed 2025-11-14 | $383.12K 10-Q · filed 2025-11-14 | $400.73K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $350.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $210.11K 10-Q · filed 2025-08-13 | $227.72K derived: sum of 3 quarters · filed 2025-08-13 | $301.95K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$140.70K 10-Q · filed 2025-05-14 | -$123.09K derived: sum of 2 quarters · filed 2025-05-14 | -$48.86K derived: sum of 3 quarters · filed 2025-05-14 | $195.71K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $17.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $91.84K derived: sum of 2 quarters · filed 2025-03-28 | $336.41K derived: sum of 3 quarters · filed 2025-03-28 | $466.89K 10-K · filed 2025-03-28 |
| 2023-09-30 | $74.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $318.80K derived: sum of 2 quarters · filed 2024-11-14 | $449.28K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $244.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $375.05K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $130.48K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |